# üî¨ Cysteamine Path Analysis Report

*Generated: 2025-12-07 14:00:25*

## 1. Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB00847 |
| **Drug Name** | Cysteamine |
| **Type** | drug |

## 2. Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 100 |
| **Unique Diseases** | 56 |
| **Mean Attention** | 0.5935 |
| **Std Attention** | 0.0818 |
| **Min Attention** | 0.4486 |
| **Max Attention** | 0.7335 |

### Paths by Hop Count

| Hops | Count |
|------|-------|
| 1 | 17 |
| 2 | 400 |
| 3 | 400 |
| 4 | 400 |
| 5 | 400 |

## 3. Path Type Summary

| Path Type | Count | Description |
|-----------|-------|-------------|
| Drug Similarity | 84 | Paths through similar drugs |
| Protein Target | 0 | Paths through protein targets |
| Pathway | 0 | Paths through biological pathways |
| Biological Process | 0 | Paths through biological processes |
| Other | 16 | Other connection types |

### Key Similar Drugs

| Similar Drug | Max Attention | # Diseases |
|--------------|---------------|------------|
| Asenapine | 0.8577 | 70 |
| Epinastine | 0.8483 | 4 |
| Promethazine | 0.8453 | 8 |
| Ranitidine | 0.8178 | 2 |

## 4. Top 20 Paths (by Combined Score)

### Path #1: actinic keratosis (disease)

**Path:**
```
[Cysteamine] --(0.546)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5462 |
| Combined Score | 0.5462 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat actinic keratosis (disease) based on embedding similarity.

---

### Path #2: pseudotumor cerebri

**Path:**
```
[Cysteamine] --(0.543)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5426 |
| Combined Score | 0.5426 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat pseudotumor cerebri based on embedding similarity.

---

### Path #3: neurotic disorder

**Path:**
```
[Cysteamine] --(0.542)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5424 |
| Combined Score | 0.5424 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat neurotic disorder based on embedding similarity.

---

### Path #4: active peptic ulcer disease

**Path:**
```
[Cysteamine] --(0.541)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5411 |
| Combined Score | 0.5411 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat active peptic ulcer disease based on embedding similarity.

---

### Path #5: cystinosis

**Path:**
```
[Cysteamine] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5381 |
| Combined Score | 0.5381 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat cystinosis based on embedding similarity.

---

### Path #6: intracranial hypertension

**Path:**
```
[Cysteamine] --(0.536)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5365 |
| Combined Score | 0.5365 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat intracranial hypertension based on embedding similarity.

---

### Path #7: leukopenia

**Path:**
```
[Cysteamine] --(0.530)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5303 |
| Combined Score | 0.5303 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat leukopenia based on embedding similarity.

---

### Path #8: bone fracture

**Path:**
```
[Cysteamine] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5266 |
| Combined Score | 0.5266 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat bone fracture based on embedding similarity.

---

### Path #9: dysthymic disorder

**Path:**
```
[Cysteamine] --(0.511)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5107 |
| Combined Score | 0.5107 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat dysthymic disorder based on embedding similarity.

---

### Path #10: anxiety disorder

**Path:**
```
[Cysteamine] --(0.508)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5081 |
| Combined Score | 0.5081 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat anxiety disorder based on embedding similarity.

---

### Path #11: gallbladder disease

**Path:**
```
[Cysteamine] --(0.508)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5079 |
| Combined Score | 0.5079 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat gallbladder disease based on embedding similarity.

---

### Path #12: skin disease

**Path:**
```
[Cysteamine] --(0.506)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5061 |
| Combined Score | 0.5061 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat skin disease based on embedding similarity.

---

### Path #13: brain disease

**Path:**
```
[Cysteamine] --(0.504)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5044 |
| Combined Score | 0.5044 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat brain disease based on embedding similarity.

---

### Path #14: seborrheic keratosis

**Path:**
```
[Cysteamine] --(0.501)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5012 |
| Combined Score | 0.5012 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat seborrheic keratosis based on embedding similarity.

---

### Path #15: liver disease

**Path:**
```
[Cysteamine] --(0.497)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4973 |
| Combined Score | 0.4973 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Cysteamine may treat liver disease based on embedding similarity.

---

### Path #16: angioedema

**Path:**
```
[Cysteamine] --(0.845)--> [Promethazine] --(0.551)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6980 |
| Combined Score | 0.4936 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Cysteamine is similar to Promethazine, which is associated with angioedema. This suggests shared therapeutic mechanisms.

---

### Path #17: angioedema

**Path:**
```
[Cysteamine] --(0.845)--> [Promethazine] --(0.551)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6980 |
| Combined Score | 0.4936 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Cysteamine is similar to Promethazine, which is associated with angioedema. This suggests shared therapeutic mechanisms.

---

### Path #18: allergic rhinitis

**Path:**
```
[Cysteamine] --(0.845)--> [Promethazine] --(0.550)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6977 |
| Combined Score | 0.4933 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Cysteamine is similar to Promethazine, which is associated with allergic rhinitis. This suggests shared therapeutic mechanisms.

---

### Path #19: allergic rhinitis

**Path:**
```
[Cysteamine] --(0.845)--> [Promethazine] --(0.550)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6977 |
| Combined Score | 0.4933 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Cysteamine is similar to Promethazine, which is associated with allergic rhinitis. This suggests shared therapeutic mechanisms.

---

### Path #20: liver failure

**Path:**
```
[Cysteamine] --(0.858)--> [Asenapine] --(0.536)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6967 |
| Combined Score | 0.4927 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Cysteamine is similar to Asenapine, which is associated with liver failure. This suggests shared therapeutic mechanisms.

---

## 5. Interpretation Guidelines

### Attention Score Scale

| Score Range | Confidence | Interpretation |
|-------------|------------|----------------|
| ‚â• 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High | Strong biological relationship |
| 0.60 - 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê High | Good evidence for connection |
| 0.50 - 0.60 | ‚≠ê‚≠ê‚≠ê Medium | Moderate support |
| 0.40 - 0.50 | ‚≠ê‚≠ê Low | Weak connection |
| < 0.40 | ‚≠ê Very Low | Speculative |

### How to Use This Report

1. **Prioritize high-scoring paths**: Focus on paths with combined scores > 0.45
2. **Validate intermediate nodes**: Cross-reference proteins/drugs with literature
3. **Consider path length**: Shorter paths (2-3 hops) are generally more reliable
4. **Check for known associations**: Some paths may represent known indications

---

*Report generated by TxGNN Path Analysis Pipeline*